Zhu Shengyu, Liu Jianjiang, Shen Bin, Xu Huali, Zhong Wei, Jin Sheng
Department of Radiotherapy, Shaoxing Second Hospital, Shaoxing, Zhejiang, China.
Department of Radiotherapy, Shaoxing People's Hospital, Shaoxing, Zhejiang, China.
Front Oncol. 2025 Apr 3;15:1534739. doi: 10.3389/fonc.2025.1534739. eCollection 2025.
Cryotherapy plays a crucial role in managing radio-recurrent prostate cancer (PCa) after initial treatment. This study aims to provide a comprehensive review of its effectiveness and associated complications.
A systematic review was conducted using PubMed and EMBASE databases up to June 2024, focusing on recurrence-free survival (RFS) with salvage cryotherapy across various subgroups. Severe complications were also assessed. Survival curves were reconstructed using WebPlotDigitizer and a newly developed Shiny application. The incidence of complications was summarized with a 95% confidence interval (CI) using a random-effects model. Complications were evaluated using the Clavien-Dindo Scale (CDS).
Thirty-six studies were included, with 15 papers (3174 patients) contributing to survival curve reconstruction. Among 1593 patients treated with salvage cryotherapy, the median RFS was 56.7 months, with 2-, 3-, and 5-year rates of 67.6%, 59.5%, and 47.3%, respectively. Factors associated with better RFS included a longer time from primary treatment to salvage therapy (TRS) [> 70 months vs. < 70 months, hazard ratio (HR) (95% CI):0.75(0.58-0.97), p=0.031], lower pre-salvage prostate-specific antigen (PSA) levels [< 5 ng/mL vs. > 5 ng/mL, HR (95% CI):0.78 (0.65-0.93), p=0.005], salvage whole-gland cryotherapy (SWC) [whole vs. focal, HR (95% CI):0.45 (0.37-0.56), p < 0.001], neoadjuvant androgen deprivation therapy (ADT) [Yes vs. No, HR (95% CI):0.79 (0.69-0.89), p < 0.001], and higher adjuvant ADT usage [16.5-34.2% vs. 0-10.5%, HR (95% CI):0.47(0.39-0.56), p < 0.001]. Concerning severe complications, 78 out of 876 patients (8.9%, 95% CI: 7-11) experienced genitourinary (GU) events, 53 out of 633 patients (8.5%, 95% CI: 6-11) suffered from urinary incontinence, 15 out of 493 patients (3.0%, 95% CI: 2-5) had urethral sloughing/stenosis, and 6 out of 522 patients (1.1%, 95% CI: 0-2) developed recto-urethral/vesical fistula. No cases of severe haematuria, urinary tract infection, or urinary retention were reported.
Cryotherapy demonstrates a favorable safety profile and significant RFS benefits for salvage treatment of radio-recurrent PCa. Longer TRS, lower pre-salvage PSA, SWC, and peri-salvage ADT usage appear to be promising prognostic factors for RFS. However, confirmation of these findings requires randomized controlled trials (RCTs) due to the low evidence levels and study heterogeneity.
冷冻疗法在初始治疗后放射性复发性前列腺癌(PCa)的管理中起着关键作用。本研究旨在全面综述其有效性及相关并发症。
截至2024年6月,使用PubMed和EMBASE数据库进行系统综述,重点关注不同亚组挽救性冷冻疗法的无复发生存期(RFS)。还评估了严重并发症。使用WebPlotDigitizer和新开发的Shiny应用程序重建生存曲线。采用随机效应模型以95%置信区间(CI)总结并发症发生率。使用Clavien-Dindo量表(CDS)评估并发症。
纳入36项研究,其中15篇论文(3174例患者)用于生存曲线重建。在1593例接受挽救性冷冻疗法的患者中,中位RFS为56.7个月,2年、3年和5年生存率分别为67.6%、59.5%和47.3%。与更好的RFS相关的因素包括从初次治疗到挽救性治疗的时间更长(TRS)[>70个月 vs. <70个月,风险比(HR)(95%CI):0.75(0.58 - 0.97),p = 0.031]、挽救性治疗前前列腺特异性抗原(PSA)水平较低[<5 ng/mL vs. >5 ng/mL,HR(95%CI):0.78(0.65 - 0.93),p = 0.005]、挽救性全腺冷冻疗法(SWC)[全腺 vs. 局部,HR(95%CI):0.45(0.37 - 0.56),p < 0.001]、新辅助雄激素剥夺治疗(ADT)[是 vs. 否,HR(95%CI):0.79(0.69 - 0.89),p < 0.001]以及更高的辅助ADT使用率[16.5 - 34.2% vs. 0 - 10.5%,HR(95%CI):0.47(0.39 - 0.56),p < 0.001]。关于严重并发症,876例患者中有78例(8.9%,95%CI:7 - 11)发生泌尿生殖系统(GU)事件,633例患者中有53例(8.5%,95%CI:6 - 11)出现尿失禁,493例患者中有15例(3.0%,95%CI:2 - 5)发生尿道脱落/狭窄,522例患者中有6例(1.1%,95%CI:0 - 2)出现直肠 - 尿道/膀胱瘘。未报告严重血尿、尿路感染或尿潴留病例。
冷冻疗法在放射性复发性PCa的挽救性治疗中显示出良好的安全性和显著的RFS益处。更长的TRS、更低的挽救性治疗前PSA、SWC以及挽救性治疗期间ADT的使用似乎是RFS有前景的预后因素。然而,由于证据水平低和研究异质性,这些发现需要随机对照试验(RCT)来证实。